Results: Coeliac patients had more EIM (62%) than those with functional disorders (33%). The most common EIM in coeliac children were poor growth (27%) and anaemia (18%). Children with coeliac disease often showed fatigue (8%) and symptoms affecting the skin (15%), nervous system (9%) and joints (6%). Coeliac patients with EIM as their main clinical presentation had more severe symptoms and histological damage at diagnosis than those with gastrointestinal presentation and screen-detected cases. The subgroups did not differ with regard to other clinical and laboratory parameters and dietary adherence. Concomitant EIM were also common in children diagnosed because of gastrointestinal presentation (60%) and by screening (37%).
INTRODUCTION
The classical clinical presentation of coeliac disease is earlyonset diarrhoea and malabsorption, with other common gastrointestinal symptoms being abdominal pain, bloating, nausea and constipation. Despite this, patients may also present with a variety of extraintestinal manifestations (EIM), for example poor growth, increased liver enzymes, dermatitis herpetiformis or other rashes, arthritis and various neurological symptoms (1) (2) (3) . It has been suggested that these atypical symptoms may occur even more frequently than the classical gastrointestinal presentation (1, 2, 4) .
Although many EIM of coeliac disease have been known for some time (5) , their actual prevalence is poorly defined. It is even more unclear whether the presence of such symptoms affects the severity of histological damage and other characteristics of coeliac disease at the time of diagnosis. Either the great majority of coeliac disease sufferers currently remain unrecognised, or there is an unacceptably long diagnostic delay (6) . A better understanding of the heterogeneous EIM would increase diagnostic efficacy and prevent the unnecessary burden, and possibly the severe complications, associated with unrecognised coeliac disease.
Abbreviations
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Key notes
This study investigated the prevalence of extraintestinal manifestations (EIM) and their association with other disease features in paediatric coeliac disease. We found that EIM were common in children with untreated coeliac disease and their presence was associated with more severe clinical and histological presentation. In addition, the 511 children with coeliac disease had higher levels of EIM than the 180 children with functional gastrointestinal disorders we studied.
The aim of this study was to investigate the prevalence of EIM in children with coeliac disease. To benchmark the observed prevalence, they were compared with children suffering from functional gastrointestinal symptoms. In addition, we sought to establish whether the main clinical presentation of coeliac disease, namely extraintestinal symptoms versus gastrointestinal symptoms and screendetected symptoms, affected other disease features and the patients' responses to a gluten-free diet.
PATIENTS AND METHODS
Study subjects and design
The study was carried out in Finland, at the Center for Child Health Research, University of Tampere and Tampere University Hospital, and in the Department of Pediatric Gastroenterology of Tampere University Hospital. We included all children under the age of 18 diagnosed with coeliac disease from 2003 to 2014 or functional gastrointestinal disorder from 2007 to 2013. Children with an uncertain diagnosis or potential coeliac disease were excluded from further analyses. Medical information was collected from the hospital patient records and from our regularly updated paediatric research database, which has previously been described (4) . From 2012 onwards, the patients with coeliac disease were enrolled as part of a prospective patient collection, but all the other study data were collected retrospectively.
The diagnosis of coeliac disease was based on the demonstration of small-bowel mucosal villous atrophy and crypt hyperplasia (7) . Functional gastrointestinal disorder was diagnosed in children who had undergone meticulous clinical and laboratory investigations and gastrointestinal endoscopy. These included intestinal biopsies because of undefined abdominal symptoms, such as pain, dyspepsia and nausea, without findings suggestive of any organic disease (8) .
Clinical information, including the presence of EIM at diagnosis as reported by the attending physician, was collected on all the children. Coeliac patients also underwent analyses of the disease-specific transglutaminase 2 and endomysial antibodies and other relevant laboratory parameters, as described below. Furthermore, the presence of concomitant associated conditions such as type 1 diabetes mellitus, autoimmune thyroidal disease and Down syndrome was noted. After these analyses, children with coeliac disease were further divided into those diagnosed because of extraintestinal or gastrointestinal manifestations and those who were detected during at-risk group screening. The groupings were carried out on the basis of the original notes in the medical record. These three subgroups were compared in terms of clinical characteristics, histology and serology and adherence and responses to a gluten-free diet.
The collection of patient information from the medical records was approved by the Department of Pediatrics, Tampere University Hospital. In addition, prospective patient enrolment and data gathering were accepted by the Ethics Committee of the Pirkanmaa Hospital District. All participating children and/or their parents provided written informed consent, depending on the patient's age.
Presence of EIM
The possible presence of EIM was recorded for all study children. These features included skin symptoms, such as dermatitis herpetiformis, atopic dermatitis, erythema nodosum, or an unspecified rash; anaemia; poor growth; dental enamel defects; and neurological symptoms, such as migraine or other headaches and gluten ataxia. They also included arthritis or other joint symptoms; recurrent aphthous ulcers and other mouth symptoms; hypertransaminasaemia, defined as alanine aminotransferase >40 U/L; fatigue; eye symptoms, such as episcleritis or uveitis; and other coeliac disease-associated extraintestinal symptoms as described in the literature (1, 2, 9) . Anaemia was defined based on age-and gender-specific reference values, as previously described in detail (10) . Poor growth was defined as an abnormal deceleration of growth compared with age-and gender-specific reference charts or growth below the expected target (3) . This definition is meant to be a sensitive screening tool for early detection of possibly treatable problems and does not necessarily mean that the child will have abnormal growth.
The severity of symptoms at diagnosis was determined on the basis of the clinical picture as reported by the clinician. Mild were occasional disturbing symptoms, moderate were symptoms that were more distracting or frequent, and severe were symptoms that seriously disturbed daily life.
Coeliac disease serology and laboratory parameters Serum transglutaminase 2 antibodies were measured using a conventional ELISA (Phadia AB, Uppsala, Sweden) before 2011 or an automatised human recombinant-based EliA assay (Phadia AB) from 2011 onwards. In our laboratory, a transglutaminase 2 value of ≥7 U/L is considered positive and the maximum reported value is 120 U/L. Serum endomysial antibodies were measured by indirect immunofluorescence using human umbilical cord as a substrate, as previously described (11) . An endomysial dilution of 1: ≥5 was considered positive, and positive sera were further diluted from 1:50 to 1:4000 until negative.
The following laboratory values measured from blood samples at the time of coeliac disease diagnosis were collected from each child when available: haemoglobin (g/L), mean corpuscular volume (fL), total iron (lmol/L), alanine aminotransferase (U/L), ferritin (lg/L), transferrin receptor 1 (mg/L), alkaline phosphatase (U/L), albumin (g/L), thyroid-stimulating hormone (mU/L) and thyroxin (pmol/L).
Small-bowel mucosal morphology
At least four forceps biopsy samples were taken from the distal duodenal mucosa and from the duodenal bulb from 2012 onwards in all cases where coeliac disease was suspected. The specimens were further processed and analysed in the hospital pathology unit. Only correctly oriented specimens were accepted for further microscopic analyses. If there was poor orientation, new cuttings were requested according to our standard operating procedures. In this study, the severity of the mucosal damage was categorised, based on the hospital pathologist's original grading, into partial, subtotal and total villous atrophy.
Adherence and responses to a gluten-free diet All patients with coeliac disease were placed on a glutenfree diet within one to four weeks of diagnosis, under the supervision of a qualified dietician. Adherence to the diet was categorised as strict diet, occasional lapses and no diet and evaluated during follow-up visits, based on family interviews and the results of serology, as previously described (12) . The patient's response to the diet was also assessed and classified. A response was defined as the alleviation of symptoms and normalised or constantly decreasing coeliac autoantibody levels, and no response was defined as persistent symptoms and/or positive autoantibodies.
Statistical analysis
All statistical analyses were performed using SPSS for Windows, version 21.0 (IBM, New York, NY, USA). Differences between the groups were compared by the Mann-Whitney U-test, the Kruskal-Wallis test, Pearson's chi-square test and Fisher's exact test. Data are expressed as either medians with upper and lower quartiles or as percentages. A p value of <0.05 was considered significant.
RESULTS
The final study cohort comprised 511 children with coeliac disease and 180 with functional gastrointestinal disorders. The coeliac patients were younger than those with functional gastrointestinal disorders, with a median age of 7.6 (4.8-11.6) versus 10.6 (6.8-13.7) years, and they were more likely to be girls (65 vs 53%) ( Table 1) . EIM were present almost twice as often in coeliac disease than functional disorders (62 vs 33%) ( Table 1 ). The most common EIM in coeliac disease were poor growth (27%), anaemia (18%) and skin symptoms (15%), and other frequent presentations were hypertransaminasaemia (9%), neurological symptoms (9%), fatigue (8%) and joint symptoms (6%). Dermatitis herpetiformis, a well-known skin manifestation of coeliac disease, was found in eight (2%) children with coeliac disease. Recurrent aphthous ulcers were rare in both groups, and dental enamel defects were found only in three children with coeliac disease. A variety of other EIM were reported in patients with coeliac disease (Table 1) .
The main reason for suspected coeliac disease was EIM in 116 (23%) patients and gastrointestinal presentation in 249 (49%) patients. A further 146 (29%) patients were detected during screening of high-risk groups. The most common indications for screening were a family risk of coeliac disease (42%) and previously diagnosed type 1 diabetes (12%). Concomitant EIM were also common in the two latter groups, and these patients displayed particularly dermatological and neurological symptoms, poor growth, fatigue, anaemia and hypertransaminasaemia (Table 2) .
We also analysed the children with coeliac disease based on whether they were diagnosed by EIM, gastrointestinal symptoms or screening. This showed that children with EIM as the main presentation had the degree of villous atrophy more severe than those diagnosed by screening or gastrointestinal symptoms (Fig. 1A) , while screen-detected children had the highest levels of haemoglobin, albumin and transglutaminase 2 ( Table 3) . There was also a clinically small, but statistically significant (p = 0.032), difference in the median haemoglobin values between the three subgroups (123, 124 and 126 g/L, respectively). The three subgroups did not differ with regard to other laboratory values, growth parameters and age (Table 3) , gender distribution (girls 64, 67 and 62%, p = 0.550) and prevalence of coeliac disease-associated conditions (10, 10 and 17%, p = 0.114). The severity of symptoms prior to diagnosis was considered mild in 22% and moderate or severe in 78% of children with EIM presentation, and the corresponding figures in those with gastrointestinal presentation were 53 and 47% (p < 0.001). In addition, 45% of the screen-detected children reported mild and 14% moderate symptoms. Children in all three coeliac disease subgroups showed excellent and practically equal adherence to the gluten-free diet (Fig. 1B) . Likewise, the beneficial response to dietary treatment was comparable between the groups: EIM 98%, gastrointestinal 96% and screen-detected 97% (p = 0.556).
DISCUSSION
There were two main findings in the present study. First, we observed that EIM were clearly overrepresented in children with untreated coeliac disease compared to children with functional gastrointestinal disorders. Second, the presence of EIM at coeliac disease diagnosis was associated with a more severe clinical and histological presentation.
We found that particularly common EIM in children with coeliac disease were poor growth, anaemia and skin symptoms. In fact, poor growth was noted in almost onethird of the coeliac patients at diagnosis. This was in line with the findings of Jericho et al. (13), who reported a prevalence of 33% for growth failure in paediatric coeliac disease. On the other hand, markedly lower (12, 14, 15) and higher (16) frequencies have been reported by other studies. Apart from differences in study design and population, the inconsistent results might be, at least partly, explained by variable definitions. We defined poor growth using specific Finnish growth references, which have all been well validated and may even lead to improved coeliac disease diagnostics (17) . However, these screening charts are more sensitive for growth variations than the more widely used World Health Organization criteria, which explains the unusually high number of children with abnormal growth in the functional gastrointestinal disorder group. This may also complicate comparisons with previous studies. Poor growth was classified here as an EIM because it might also be caused by other pathophysiological mechanisms than just malabsorption (2) .
The second most common EIM in coeliac disease was anaemia. Although the incidence was about as common as observed in our other recent studies (4, 10) , the prevalence of anaemia was similar to poor growth in that it was markedly lower in this study than in most previous reports (14, 15, 18) . One explanation could be that, overall, nutritional status is good in Finnish children and anaemia and iron deficiency are rare. Moreover, the presence of anaemia at the time of coeliac disease diagnosis is known to be associated with a severe clinical and histological presentation and long diagnostic delay (10, 18) , and these are both less frequent in Finland than in many other countries (4). Similarly as with growth failure, the definition of anaemia as an EIM can be debated, but the concept is based on evidence that anaemia in coeliac disease is not necessarily associated with the degree of intestinal malabsorption (2, 10, 19) . Besides iron deficiency, it can also be caused by factors such as chronic inflammation and bone marrow suppression (20) . In general, the pathophysiology of EIM in coeliac disease is poorly known, but there are probably several mechanisms, such as chronic inflammation, nutritional deficiencies and hormonal changes (2). Furthermore, autoantibodies targeted, for example, against the brain in gluten ataxia (21) and the bones in osteoporosis (22) may not be just surrogate markers, but may also play a role in the pathogenesis. Skin manifestations were another common finding in untreated coeliac disease. We found that eight (1.6%) children had dermatitis herpetiformis, a well-known EIM of coeliac disease, whereas the association between other rashes and coeliac disease is less clear. Unspecific skin symptoms, such as viral exanthemas and atopic eczema, are rather common in children, but the overrepresentation of rashes in coeliac children compared to those with functional symptoms in this study suggests that these were indeed related to coeliac disease. The relative rarity of dermatitis herpetiformis in the children in our study was in accord with the latest evidence (23) . There have been a dearth of studies regarding the prevalence of other rashes in patients with coeliac disease, but two papers have reported figures comparable to ours (12, 13) .
Of the other EIM, neurological and joint symptoms, fatigue and hypertransaminasaemia were particularly frequent in our patients with coeliac disease. The prevalence of neurological symptoms was consistent with findings from Finland and Italy (14, 15) , and they were reported in up to 51% of Israeli children with coeliac disease (12) . Fatigue and joint symptoms were more common in children with coeliac disease than in those with functional disorders, but less common than reported by other authors (18, 24, 25) . In our earlier study, 15% of children with untreated coeliac disease had elevated alanine aminotransferase values (26) and even higher rates have been reported (27) . Nevertheless, this study used a higher cut-off for increased values than our previous study, as mild hypertransaminasaemia usually has no major clinical significance (26) . In contrast to the above-mentioned symptoms, mouth and teeth findings were quite rare. The prevalence of enamel defects and aphthous ulcers has also varied substantially in other studies, probably due to their vague nature and difficult definition (14, 28) . Altogether, the marked variations between studies in the prevalence of extraintestinal symptoms emphasise the need for prospective studies.
We found that children with EIM had more severe duodenal lesions than those with gastrointestinal presentation. The histology has not previously been studied in these circumstances, but Mubarak et al. (18) reported that EIM were more frequent in subjects with high transglutaminase 2 values. The surprising presence of the highest antibody levels in the screen-detected children in the present study might have been due to clinicians' reluctance to perform gastroscopy in these often asymptomatic patients with low positive serology. In any case, the association between clinical and histological presentation in coeliac disease indicates a pathogenic link. In inflammatory bowel disease, for instance, antigen cross-reactivity, malabsorption and certain human leucocyte antigen phenotypes are thought to be associated with the presence of EIM (29) , while there is a lack of similar studies in coeliac disease. Aside from the previously mentioned factors in inflammatory bowel disease, the relationship between intestinal microbiota and EIM is particularly interesting (30) . Even though EIM are associated with more severe presentation in both conditions, patients with coeliac disease generally have a general better prognosis as the pathogenic process can be reversed by specific treatment.
The main strengths of the present study were the large cohorts of representative patients with coeliac disease and controls and the wide range of clinically relevant data available on each child. We recognise that there were also several limitations. The main limitation was the retrospective design and lack of systematic questionnaires for the evaluation of symptoms. This might have led, for example, to us underestimating mild or vague symptoms such as enamel defects, aphthous stomatitis and fatigue. Retrospective grouping of the study children to those with EIM or gastrointestinal presentation was challenging and inevitably subjective, particularly if a patient was suffering from more than one symptom simultaneously. The lack of prospective data might also have affected the assessment of dietary responses, as physicians may have focused mostly on alleviating classical gastrointestinal symptoms. Moreover, we were not able to find out whether the symptoms disappeared totally when the children were on a glutenfree diet, which would have further supported the causal relationship between EIM and coeliac disease. The retrospective design led to missing growth data and laboratory values from some of the patients, which may have caused by selection bias. We also were not able to evaluate the exact diagnostic latency in coeliac disease. This would have been important, as it is possible that the frequency of EIM was affected by the duration of untreated disease. In addition, the possibility that asymptomatic children with low positive serology were less frequently biopsied might have biased the differences between screen-detected and symptomatic patients. Finally, the lack of a standardised international definition of extraintestinal symptoms makes comparing our data with other studies challenging.
CONCLUSION
We found that EIM were common in children with coeliac disease and were associated with a more severe clinical and histological presentation. It is therefore important that clinicians consider the possibility of coeliac disease as a cause for variable EIM and specifically consider their presence in newly diagnosed coeliac patients. In the future, large multicentre prospective studies would provide even more robust information on the prevalence of EIM in coeliac disease.
